Form Type: 4

SEC EDGAR Link
Accession Number:0001209191-23-053351
Date:2023-10-19
Issuer: ULTRAGENYX PHARMACEUTICAL INC. (RARE)
Original Submission Date:

Reporting Person:

KAKKIS EMIL D
C/O ULTRAGENYX PHARMACEUTICAL INC.
60 LEVERONI COURT NOVATO, CA 94949

Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
Title of SecurityTransaction Date2a. Deemed Execution Date Transaction CodeSharesAcquired or DisposedPrice per share 5. Amount of Securities Beneficially Owned Following Reported Transaction 6. Ownership Form Direct or IndirectNature of Indirect Ownership
COMMON STOCK 2023-10-19 M 47,853 a $6.86 647,029 direct
COMMON STOCK 2023-10-19 S 47,853 d $33.52 599,743 direct
COMMON STOCK 2023-10-19 0 $0.00 2,263,985 indirect
Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, convertible securities
Title of Derivative Security Conversion or Exercise Price of Derivative Security Transaction Date Deemed Execution Date Transaction Code Number of Derivative Securities Acquired (A) or Disposed of (D) Date ExercisableExpiration Date Title and Amount of Securities Underlying Derivative Security Price of Derivative Security Number of derivative Securities Beneficially Owned Following Reported Transaction(s) Ownership Form: Direct (D) or Indirect (I) Nature of Indirect Beneficial Ownership
STOCK OPTION (RIGHT TO BUY) 6.86 2023-10-19 deemed execution date M 47,853 (d) 2023-11-01 common stock 47,853 $6.86 0 direct
Footnotes
IDfootnote
f1 the transactions reported on this form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person prior to february 27, 2023.
f2 the price reported in column 4 is a weighted average price. these shares were sold in multiple transactions at prices ranging from $32.57 to $34.45 inclusive. the reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the securities and exchange commission, upon request, full information regarding the number of shares sold at each separate price within the range.
f3 includes 567 shares acquired under the company's 2014 employee stock purchase plan on april 30, 2023.
f4 includes previously reported shares of common stock underlying rsus granted to the reporting person, which are subject to certain vesting conditions.
f5 the option vested with respect to 1/4th of the shares on the first anniversary of the grant date of the option and 1/48th of the shares thereafter such that the option fully vested on the fourth anniversary of the grant date.
WhaleWisdom Logo

Elevate your investments